Merus (MRUS) has agreed to give Partner Therapeutics an exclusive license to commercialize zenocutuzumab for the potential treatment of NRG1 fusion-positive cancer in the US, the companies said Monday.
Financial details of the licensing agreement weren't disclosed.
Under terms of the agreement, Partner Therapeutics will assume the full rights following a specified transition period.
In exchange, Merus will receive an upfront payment and is eligible to receive milestones and high single-digit to low double-digit royalty payments based on the annual net sales.
The US Food and Drug Administration is currently reviewing a Biologics License Application for zenocutuzumab for the treatment of patients with previously treated NRG1 fusion-positive non-small cell lung and pancreatic cancers, the companies added.
Shares of Merus were up around 3% in recent Monday premarket activity.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。